The fold‐change of Siglec‐10 downmodulation between normal and tumor cells was on average higher among CLL cases with unfavorable prognosis (uCLL vs. mCLL) (Appendix Fig S5A), however, did not reach statistical significance. This evidence concerns the gene SIGLEC10 and B-cell chronic lymphocytic leukemia.